Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4763 - N-Myc and STAT interactor (NMI) as a key determinant of chemosensitivity in breast cancer: proteomic-based computing network mapping and in vivo verification with a mouse model

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Hyebin Lee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

H. Lee1, K. Lee2, D. Han3, H. Ryu4

Author affiliations

  • 1 Radiation oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine,, 03080 - Seoul/KR
  • 2 Biomedical Research Institute, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
  • 3 Proteomic Core Facility, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
  • 4 Pathology And Proteomic Core Facility, Seoul National University Hospital (SNUH)-Yongon Campus, 110-744 - Seoul/KR
More

Resources

Abstract 4763

Background

We targeted NMI based on our previous proteomics analysis using FFPE breast cancer samples with neoadjuvant settings and text-mining analytics to verify NMI as a target agent to overcome chemoresistance through in vitro and in vivo studies.

Methods

Quantitative proteomics was analyzed for three different breast cancer cell lines with NMI gene silencing. We performed computation pathway enrichment based on domain knowledge for text-mining and bioinformatics tools to identify critical pathways related to chemotherapeutic sensitivity. A total of 8 breast cancer cell lines with or without endogenous chemoresistance were enrolled to define the important pathways and molecules in determining chemosensitivity through cell-titer glo assay, FACS, 3D spheroid and invasion assay, ROS assay by DCFDA and Mitotracker. Interaction network analyses were investigated to define the signaling pathway landscapes with public network databases and bioinformatic network evaluations. To verify the chemosensitive roles of NMI in vivo setting, we are conducting animal tests and immunostaining in human breast cancer samples where the patients received neoadjuvant chemotherapy.

Results

A total of 972 were confirmed to be significantly altered proteins after NMI gene silencing. A vast number of cell cycle-related proteins, which were downregulated considerably in NMI suppressed group led us to verify NMI's biological function on chemosensitivity through molecular biology-driven assays. Cell-titer glo assay and FACS revealed significantly induced cytotoxicity and apoptosis in both hormone receptor positive and negative groups without NMI gene after treatment with three different chemotherapeutic agents. The 3D-spheroid assay demonstrated a reduced spheroid formation in the case group. DCFDA and Mitotracker assay revealed increased intracellular and intramitochondrial ROS levels. We built biological network models based on in-silico and biology-driven assays. Currently, we are conducting in vivo validation using an animal test model and human samples.

Conclusions

Our biological evidence for NMI can provide novel insights to overcome chemo-resistance in breast cancer.

Clinical trial identification

Legal entity responsible for the study

Han Suk Ryu.

Funding

This research was suppoorted by a grant of the Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings